Evotec (0IRF) Share Price & Analysis
0IRF Stock Chart & Stats
- Day’s Range
- EUR 3.02 - EUR 3.18
- 52-Week Range
- EUR 2.41 - EUR 6.68
- Previous Close
- EUR 3.00
- Volume
- N/A
- Average Volume (3M)
- 43.69K
- Market Cap
- EUR 562.12M
- Enterprise Value
- EUR 898.74M
- Total Cash (Recent Filing)
- EUR 418.48M
- Total Debt (Recent Filing)
- EUR 417.21M
- Price to Earnings (P/E)
- ―
- Beta
- 1.26
- Next Earnings
- Apr 14, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Integrated R&D Platform
Evotec’s integrated coverage across discovery, preclinical work, and development support gives partners a broader service relationship than a single-stage provider. This model can support recurring collaboration, improve continuity across programs, and create multiple ways to participate in customers’ drug-development spending.
Revenue Growth
TTM revenue growth of 14.5% indicates that customer demand and activity across Evotec’s offering remain resilient despite the company’s profitability challenges. Sustained growth would expand the revenue base available to absorb fixed costs and could provide operating leverage if execution improves.
Manageable Leverage
Debt-to-equity of approximately 0.65 and a sizable equity base indicate that headline leverage is not yet extreme. This provides more financial flexibility than a highly levered balance sheet would offer, supporting continued investment while management works to improve profitability and cash generation.
Bears Say
Persistent Cash Burn
Negative operating cash flow and deeply negative free cash flow show that the current business is not funding itself through operations. Persistent cash burn reduces financial flexibility, limits internally funded investment, and increases the importance of restoring profitability or securing additional funding.
Weak Profitability
Low gross margins combined with materially negative EBIT and net margins indicate that revenue growth is not currently translating into durable earnings. This weak conversion raises execution risk, limits reinvestment capacity, and leaves results vulnerable if costs remain elevated or growth moderates.
Eroding Equity Returns
A roughly negative 26% return on equity and declining equity base show that ongoing losses are absorbing shareholder capital rather than compounding it. Continued erosion could reduce balance-sheet resilience over time and constrain the company’s ability to pursue growth without external financing.
0IRF FAQ
What was Evotec’s price range in the past 12 months?
What is Evotec’s market cap?
When is Evotec’s upcoming earnings report date?
How were Evotec’s earnings last quarter?
Is Evotec overvalued?
Does Evotec pay dividends?
What is Evotec’s EPS estimate?
How many shares outstanding does Evotec have?
What happened to Evotec’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Evotec?
What is the TipRanks Smart Score and how is it calculated?
Evotec Stock Smart Score
Company Description
Evotec
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Christian Wojczewski
- Employees
- 4,461
- Website
- www.evotec.com
- Address
- Essener Bogen 7, Hamburg, HA, 22419, DE
Evotec (0IRF) Earnings & Revenues
0IRF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 3 | 8 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 8 | 0 | 4 |
